HLA-homozygous iPSC-cardiomyocyteE Aggregate manufacturing technologies for allogenic cell therapy to the heart The European Union Research & Innovation Action is funding the HEAL research project, which involves ten partners from all over Europe and Israel, with more than six million euros, of which the Medical School Hannover (MHH) is the coordinating institution. One goal of the network is establishing new tools and expertise for accelerating the development of advanced human induced pluripotent stem cell (iPSC)-based therapies. The project also aims for overcoming scientific, regulatory and in particular safety hurdles, necessary to initiate a first-in-man (FIM) clinical trial for the therapeutic administration of allogeneic, human leukocyte antigen (HLA)-homozygous iPSC-cardiomyocyte aggregates, for improving the function of damaged hearts.